


VALUATION MULTIPLES

Forward EV / EBITDA Multiples (monthly to 31/10/2019) Source: FactSet Research Systems Inc.

Multiples in the Healthcare sector have increased over the period. At the end of October, the sector traded on a forward EV / EBITDA multiple of 11.7x, compared to the ASX200 on 10.1x.



Average Values and Trading Multiples (values as at 26/11/2019) Source: FactSet Research Systems Inc.

Subsector	Enterprise Value (\$ m)	EV/EBITDA FY2020	EV/EBIT FY2020	Price / Earnings FY2020
Aged Care	3,441	10.3x	15.3x	22.8x
Animal Health	265	7.1x	8.4x	10.8x
Biotech	128,136	26.9x	31.2x	39.7x
Hospitals & Clinics	41,437	10.6x	15.5x	22.5x
Medical Devices	13,079	28.8x	32.2x	43.5x
Healthcare	187,442	11.7x	15.8x	22.1x

Note: Multiples are based on the forward year of the unreported period, which for the majority of companies in the sector is FY2020. Difference in forward EV/EBITDA multiples between Figure and Table are representative of the timing difference between month-end result, and current day result.

MERGER & ACQUISITION NEWS...



Value: \$170m (estimated)

Pemba Capital Partners, along with the management of **ONCALL**, has agreed to acquire the company, in a management buyout transaction. **ONCALL** is an Australia-based provider of services in emergency and non-emergency situations. The value of the deal is estimated at AUD 170m.



Value: \$10m

PRP Group Pty Ltd, a Australia-based investment company (SPV), has agreed to acquire a 70.33% stake in **PRP Diagnostic Imaging Holdings Limited**, an Australia-based company engaged in operation of radiology and nuclear medicine clinics, providing services including digital X-Ray, mammography, 3D breast tomosynthesis, CT, nuclear medicine, PET/CT, MRI, ultrasound, OPG, bone mineral density, from **HengKang Medical Group Co., Ltd.**, a China-based SZSE-listed company engaged in the research, development, manufacture and sale of traditional Chinese medicines, for a total consideration of AUD 10m.



Value: \$70m

OBJ Limited, an Australia-based ASX-listed developer of magnetic, micro-array drug and ingredient delivery technologies, has agreed to acquire **Export Corp Australia**, an Australia-based company operating as an importer and distributor of sports nutrition.

UNDER THE MICROSCOPE...

- **Phylogica**, an Australian peptide drug discovery company, has increased its shareholding in **Vision Pharma** to 90% following an AUD 15m investment.
- **Esencia Healthcare**, an Australia-based allied health business, is said to be seeking private equity buyers. The business had FY18 revenue of AUD 28.9m and EBITDA of AUD 9.6m.
- Australian cannabis business **Creso Pharma** and **PharmaCielo**, a Toronto, Ontario-based cultivator and producer of medicinal-grade cannabis oil, have agreed to terminate the previously announced scheme of arrangement based on **Creso Pharma's** independent expert report which concluded that the scheme is neither fair nor reasonable and not in the best interests of **Creso Pharma** shareholders.
- **Vir Pharma**, an Australian medicinal cannabis business, is planning to list on the ASX in 2020. The firm will also raise AUD 4m through the issue of pre-IPO convertible notes, which will convert to shares in the IPO at a discounted price.
- **CareLynx**, a privately held Australian care facility management software developer, has appointed IFL Ventures to seek up to AUD 5m in a Series A raise. The capital raised will be used to further enhance **CareLynx's** technology, marketing and business development activities.
- **Kira Biotech**, an Australian immunology company, has raised AUD 20m in a Series A funding round led by **OneVentures**, **IP Group** and the **Advance Queensland Business Development Fund**. Proceeds will be used to develop therapeutics targeting difficult-to-treat immune system disorders, and to advance its lead candidate through phase-1 human studies.
- **Blackmores Limited** has acquired **Catalent Australia Holdings'** manufacturing facility in Victoria, representing Blackmores' expansion into soft-gel and tablet manufacturing. The completion payment for the factory was AUD 33m.
- **The Optical Company**, an Australia-based eye care business, is seeking buyers to become capital partners to help with its growth ambitions. The business owns over 40 eye care stores and reports annual earnings of around AUD 6m.

CONTACT DETAILS

If you are interested in specific information regarding mergers and acquisitions in the Healthcare sector, please contact David Hassum or Michael Kakanis.

Name	Position	Phone	Email
Sharon Doyle	Managing Director	(07) 3218 9122	sdoyle@interfinancial.com.au
Paul Keehan	Chairman	(07) 3218 9100	pkeehan@interfinancial.com.au
Mark Steinhardt	Head of M&A	(07) 3218 9105	msteinhardt@interfinancial.com.au
Brad Shaw	Chief Operating Officer	(07) 3218 9100	bshaw@interfinancial.com.au
David Hassum	Director	(07) 3218 9108	dhassum@interfinancial.com.au
Andrew Wheeler	Director	(07) 3218 9107	awheeler@interfinancial.com.au
Anna Green	Director	(07) 3218 9100	agreen@interfinancial.com.au
Ted Marchant	Director	(07) 3218 9100	tmarchant@interfinancial.com.au
Sally McMillan	Associate Director	(07) 3218 9100	smcmillan@interfinancial.com.au
Brent Wall	Associate Director	(07) 3218 9102	bwall@interfinancial.com.au
Michael Kakanis	Associate	(07) 3218 9106	mkakanis@interfinancial.com.au

DISCLAIMER

This information has been sourced from the ASX, Mergermarket.com and various other public information sources. Forecasts are consensus forecasts sourced from FactSet Research Systems Inc.

Important Disclaimer – This may affect your legal rights: Because this document has been prepared without consideration of any specific person's financial situation, particular needs and investment objectives, a financial services licensee or investment adviser should be consulted before any investment decision is made. While this document is based on information from sources which are considered reliable, InterFinancial, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does InterFinancial accept any responsibility to inform you of any matter that subsequently comes to notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of InterFinancial. This report does not constitute advice to any person.

Disclosure. InterFinancial has no interest in any of the securities mentioned in this publication. However, its directors, executives or consultants may have an interest in some of the securities, directly or indirectly, which are mentioned.

InterFinancial is a member of Clairfield International, an international corporate finance firm that provides advisory services in crossborder mergers and acquisitions. Clairfield is represented by over 400 people across 22 countries, closing over 100 transactions each year.

<p>InterFinancial Corporate Finance Limited ABN: 49 136 962 966 AFSL: 341675 Level 2, 201 Charlotte Street GPO Box 975 Brisbane Queensland 4001 (07) 3218 9100 admin@interfinancial.com.au www.interfinancial.com.au</p>	
---	---